Personalized Response-Directed Surgery and Adjuvant Therapy After Neoadjuvant Ipilimumab and Nivolumab in High-Risk Stage III Melanoma: The PRADO Trial - Reijers, ILM; Menzies, AM; van Akkooi, ACJ (Nature Medicine, 2022)
et al.